Trevena (TRVN) is a biopharmaceutical company focused on developing targets and treatments for diseases affecting the central nervous system and pain relief. The main drug the company is developing is called oliceridine a mu-opioid receptor for the management of moderate-to-severe acute pain in hospitals. The company is hoping that oliceridine will replace intravenous administration of opioids drugs, the most common of which is morphine.
For the benefit of those who are unfamiliar with this company, this is just a brief history of the company's application for oliceridine so far. The company has completed